CAR T-cell Long-Term Follow-Up, Quality of Life and Adverse Reactions
Part of paid clinical trials in Memphis, Tennessee.
- Sponsor
- St. Jude Children's Research Hospital
- Study ID
- NCT07048535
- Status
- Recruiting
Conditions
- B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
To learn more about the long-term health in patients treated for B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Cluster of Differentiation antigen 19 (CD19) -redirected chimeric antigen receptor (CAR) T-cells. Primary Objective: To evaluate the feasibility of conducting standardized clinical assessments of pediatric, adolescent and young adult (AYA) B-ALL survivors post CD19-CAR T-cell therapy, treated at multiple institutions, leveraging the St Jude Lifetime Cohort (SJLIFE) clinical and research infrastructure. Exploratory Objectives: * To describe the prevalence of persistent and new/late-onset health conditions developing ≥2-years post CD19-CAR T-cell therapy in survivors of pediatric and AYA B-ALL. * To characterize neurocognitive and neurologic function in survivors ≥2-years post CD19- CAR T-cell therapy. * To characterize immune health in survivors ≥2-years post CD19-CAR T-cell therapy. * To characterize functional status in survivors ≥2-years post CD19-CAR T-cell therapy.
Key Dates
- Start date
- Oct 24, 2025
- Status verified
- Apr 2026
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2029
Study Design
- Enrollment
- 80 participants (estimated)
Primary Outcome Measure
To evaluate the feasibility of conducting standardized clinical assessments of pediatric and AYA B-ALL survivors post CD19-CAR T-cell therapy [ Time Frame: Through study completion, approximately 5 years ]
Central Contacts
- Aimee Talleur, MD888-226-4343
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 |
Find similar trials in Memphis, TN
Related Studies
- Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaPHASE1/PHASE2 · Recruiting · AstraZeneca · Duarte, California
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaPHASE1/PHASE2 · Recruiting · AstraZeneca · Birmingham, Alabama
- A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received BlinatumomabRecruiting · Arkansas Children's Hospital Research Institute · Little Rock, Arkansas